Three differentiation states risk-stratify bladder cancer into distinct subtypes

Jens-Peter Volkmer(Institute for Stem Cell Biology and Regenerative Medicine), Debashis Sahoo(Institute for Stem Cell Biology and Regenerative Medicine), Robert Chin(University of Chicago Medical Center), Philip Levy Ho(Baylor College of Medicine), Chad Tang(Institute for Stem Cell Biology and Regenerative Medicine), Antonina V. Kurtova(Baylor College of Medicine), Stephen B. Willingham(Institute for Stem Cell Biology and Regenerative Medicine), Senthil Pazhanisamy(Baylor College of Medicine), Humberto Contreras-Trujillo(Institute for Stem Cell Biology and Regenerative Medicine), Theresa A. Storm(Institute for Stem Cell Biology and Regenerative Medicine), Yair Lotan(The University of Texas Southwestern Medical Center), Andrew H. Beck(Stanford University), Benjamin I. Chung(Stanford University), Ash A. Alizadeh(Stanford University), Guilherme Godoy(Baylor College of Medicine), Seth P. Lerner(Baylor College of Medicine), Matt van de Rijn(Stanford University), Linda D. Shortliffe(Stanford University), Irving L. Weissman(Institute for Stem Cell Biology and Regenerative Medicine), Keith Syson Chan(Baylor College of Medicine)
Proceedings of the National Academy of Sciences
January 19, 2012
Cited by 265Open Access
Full Text

Abstract

Current clinical judgment in bladder cancer (BC) relies primarily on pathological stage and grade. We investigated whether a molecular classification of tumor cell differentiation, based on a developmental biology approach, can provide additional prognostic information. Exploiting large preexisting gene-expression databases, we developed a biologically supervised computational model to predict markers that correspond with BC differentiation. To provide mechanistic insight, we assessed relative tumorigenicity and differentiation potential via xenotransplantation. We then correlated the prognostic utility of the identified markers to outcomes within gene expression and formalin-fixed paraffin-embedded (FFPE) tissue datasets. Our data indicate that BC can be subclassified into three subtypes, on the basis of their differentiation states: basal, intermediate, and differentiated, where only the most primitive tumor cell subpopulation within each subtype is capable of generating xenograft tumors and recapitulating downstream populations. We found that keratin 14 (KRT14) marks the most primitive differentiation state that precedes KRT5 and KRT20 expression. Furthermore, KRT14 expression is consistently associated with worse prognosis in both univariate and multivariate analyses. We identify here three distinct BC subtypes on the basis of their differentiation states, each harboring a unique tumor-initiating population.


Related Papers

No related papers found

Powered by citation graph analysis